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The ability of 5-aminolaevulinic acid and some of its esteriﬁed derivatives to induce porphyrin accumulation has been
examined in CaNT murine mammary carcinoma cells growing in culture and as tumours in vivo. Topical or intravenous
administration of 5-aminolaevulinic acid-esters to mice bearing subcutaneous tumours produced lower porphyrin levels in the
tumour than an equimolar dose of 5-aminolaevulinic acid. Reducing the dose of intravenous hexyl- or benzyl-ALA and topical
hexyl-5-aminolaevulinic acid resulted in a dose-dependent reduction in porphyrin accumulation. A number of normal tissues
accumulated higher concentrations of porphyrins than tumour tissue following intravenous administration of 5-aminolaevulinic
acid-esters. Esterase activity in these normal tissues was greater than that in tumour tissue. In contrast to the situation in vivo,
all of the 5-aminolaevulinic acid-esters examined were at least as effective as 5-aminolaevulinic acid when applied to cloned
CaNT cells in vitro, with the drug concentration required for maximum porphyrin accumulation varying with ester chain-length.
Tumour cells growing in culture released esterase activity into the medium. These ﬁndings suggest that the efﬁcacy of 5-
aminolaevulinic esters may vary depending on the esterase activity of the target tissue, and suggest caution when interpreting
the ﬁndings of in vitro studies using these and similar prodrugs.
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Photodynamic therapy (PDT) is increasingly being used for the
treatment of many malignant and pre-malignant conditions.
Although the photosensitising drug Photofrin-II
1 has received
regulatory approval for use in a number of conditions (Dougherty
et al, 1998), patients often have to be limited to subdued lighting
for several weeks following treatment due to its prolonged reten-
tion in the skin (Carruth, 1998). In contrast, skin
photosensitivity following the systemic administration of 5-amino-
laevulinic acid (ALA), a metabolic precursor of the photosensitiser
protoporphyrin-IX (PpIX), is relatively mild and short-lived (Rick
et al, 1997). ALA-based PDT is now being investigated as a treat-
ment for several conditions (Roberts and Cairnduff, 1995; Peng et
al, 1997b).
The hydrophilic nature of ALA (Novo Rodriguez et al, 1995)
may limit its ability to penetrate through skin or cell membranes
(Peng et al, 1997a) and thereby restrict its topical use to the treat-
ment of superﬁcial disease. As a result, esteriﬁed derivatives of
ALA, which are less hydrophilic than the parent compound
(Uehlinger et al, 2000), are under investigation as possible alterna-
tives to ALA. Work in vitro has demonstrated that a number of cell
lines have the ability to take-up and metabolise certain ALA-esters
into PpIX at a faster rate, and at lower concentrations, than ALA
(Kloek and Beijersbergen van Henegouwen, 1996; Peng et al,
1996). A number of in vivo studies have suggested that topical
application of some ALA esters can result in greater PpIX accumu-
lation than similar concentrations of ALA (Peng et al, 1996; Lange
et al, 1999; van den Akker et al, 2000). In contrast, however, clin-
ical work with human solar keratoses showed methyl-ALA to
induce less PpIX than ALA (Fritsch et al, 1998).
ALA has been shown to be effective at inducing PpIX after oral,
intravenous (i.v.) or topical application in vivo (Cairnduff et al,
1995; Peng et al, 1995; van den Boogert et al, 1998). As yet, no data
regarding the systemic administration of ALA-esters have been
published. The aim of this study was to investigate the induction
of porphyrins by ALA and ALA-esters in mouse mammary carcino-
ma cells growing both in vitro and as tumours in vivo.
MATERIALS AND METHODS
Chemicals
ALA hydrochloride was synthesised using a method based on that
of Pfaltz and Anwar (1984), puriﬁed with active charcoal and re-
crystallised from acetone. Hydrochloride salts of ethyl-, propyl-,
butyl-, pentyl-, cyclohexyl-, hexyl- and benzyl-ALA were prepared
using the method described by Kloek et al (1998). Elemental analy-
sis showed them to be at least 90% pure. Unguentum Merck
1
emollient cream was obtained from Merck Ltd, Lutterworth, UK.
All other chemicals were obtained from BDH Laboratory Supplies,
Poole, UK and Sigma-Aldrich Co. Ltd., Poole, UK.
Tumour and animals
The CaNT tumour is a poorly-differentiated non-immunogenic
carcinoma, probably of mammary origin, which arose sponta-
neously in a female CBA/Gy mouse (Hewitt et al, 1973). Tumour
and initial breeding pairs of CBA/Gy mice were kindly provided
by Dr DJ Chaplin and Mr P Russell respectively (CRC Gray Labora-
tories, Middlesex, UK). Mice were housed in a 12 h light/dark cycle
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Universal Standard Rodent Diet). Once ALA or ALA-ester had been
administered, animals were maintained in subdued lighting. All
work was carried out in accordance with the UKCCCR guidelines
for use of animals in experimental neoplasia (UKCCCR 1998).
Tumours were maintained by serial transplantation for a maxi-
mum of 10 passages. For experiments, tumour fragments of
approximately 5 mm
3 were implanted subcutaneously (s.c.) into
the ﬂanks of 6–10-week-old mice (21–27 g), and allowed to grow
to 150–250 mm
3 prior to randomisation to control or treatment
groups.
Cells and cell culture
CaNT cells were harvested from tumour explants growing at 378C
in Dulbecco’s minimal essential medium (DMEM) containing 10%
foetal calf serum (Life Technologies, Paisley, UK) in an atmosphere
of 5% CO2 in air. Clones were prepared by dilution and subse-
quently shown to be tumorigenic by s.c. inoculation into CBA/
Gy mice. Cells were routinely passaged using 1% trypsin/EDTA
(Life Technologies, Paisley, UK).
ALA and ALA-ester-induced generation of porphyrins in
murine tissues
ALA (0.06–1.2 mmol kg
71) and ALA esters (0.0012–
1.2 mmol kg
71)i n1 0 m M phosphate buffered saline (PBS,
pH 7.4) were administered via a lateral tail vein. Animals were
killed at intervals up to 24 h later, and tissue samples (0.1–0.2 g
wet weight) snap-frozen in liquid nitrogen and stored at 7858C.
For topical application, ALA (20% w/w) and hexyl-ALA (0.02–
20% w/w) were prepared in Unguentum Merck
1 emollient cream
immediately prior to use. Skin overlying the tumour was shaved
and tape-stripped and 0.2 ml cream rubbed into the skin for two
minutes with a gloved ﬁnger. Control animals received 0.2 ml
cream alone. Tumour tissue was collected 1–6 h later as described
above.
Porphyrin concentrations were determined by a method modi-
ﬁed from that of Longas and Poh-Fitzpatrick (1980). The
porphyrin extraction efﬁciency of this assay has previously been
calculated as 90% (Poh-Fitzpatrick and DeLeo, 1977). Brieﬂy,
tissue samples were incubated in 1 M aqueous NaOH in the dark
at 408C for 16 h and porphyrins extracted into 4:1 ethyl acetate:a-
cetic acid. The organic layer was removed and porphyrins extracted
into 1 M aqueous HCl. Porphyrin ﬂuorescence in the resultant
aqueous layer was measured with a Kontron SFM25 ﬂuorimeter
(Kontron Instruments Ltd, Watford, UK; excitation 403 nm, emis-
sion 602 nm). A solution of haematoporphyrin was used as
ﬂuorescence standard. Data from tissues treated with ALA- or
ALA-ester were corrected by subtracting the porphyrin concentra-
tion in equivalent untreated tissues.
ALA and ALA-ester-induced generation of porphyrins in
cultured cells
Cloned CaNT cells were grown in 24-well plates until 50–75%
conﬂuent. After thorough washing in warm PBS, cells were incu-
bated in the dark for 3 h with ALA or ALA-esters in serum-free
DMEM at pH7.4. Cells were then washed twice in PBS and solubi-
lised in the dark in 0.5 ml of 26.5 M formic acid for 15 min at
room temperature. Porphyrin ﬂuorescence was determined as
described above. Cellular protein concentration was determined
in duplicate wells using the BioRad protein microassay (Biorad
Laboratories Ltd, Hemel Hempstead, UK). Porphyrin analyses were
performed in quadruplicate, and all experiments were repeated at
least twice. Data from cells treated with ALA- or ALA-ester were
corrected by subtracting the porphyrin concentration in equivalent
untreated cells.
HPLC analysis of porphyrins
Porphyrins in tissue samples or cultured cells were extracted as
described for ﬂuorimetry and the pH adjusted to 5 or above with
saturated sodium acetate. The samples were then further extracted
into ethyl acetate, washed with an equal volume of distilled water
and passed through a ﬁlter paper saturated in ethyl acetate. They
were then dried under a stream of nitrogen gas and stored in
the dark at 48C until required.
Dry porphyrin samples were dissolved in 100 ml of methanol
containing 10% HCl immediately before HPLC analysis. Reverse
phase HPLC analysis of 20 ml of reconstituted sample was
performed using a Waters Nova Pak C18 analytical column
(150 mM63.9 mm). Solvent A was 10% acetonitrile/90% ammo-
nium acetate (1 M, pH 5.16). Solvent B was 90% methanol/10%
acetonitrile. Fluorescence detection was performed at 400 nm exci-
tation and 620 nm emission. Sample absorbance was measured at
400 nm. Standards solutions of known porphyrins were used to
identify the porphyrins in samples.
Non-speciﬁc esterase assay
Non-speciﬁc esterase activities in tissue homogenates, lysates of
cultured cells and in cell-conditioned or fresh culture medium were
determined using an adaptation of the ﬂuorescein diacetate method
described by Washbrook and Riley (1997).
Statistical analysis
Statistical analyses were performed using SPSS v9.0 for Windows.
The independent-samples Student t-test was used to test the
difference between means. Normality of data was conﬁrmed using
the Kolmogorov-Smirnov statistic or Q-Q normal probability
plot.
RESULTS
ALA and ALA-ester-induced generation of porphyrins in
murine tissues
Porphyrin levels in the CaNT tumour were highest 1 h after i.v.
administration of ALA or ALA-esters (0.12 mmol kg
71), except
in the cases of propyl- and cyclohexyl-ALA which did not induce
porphyrin accumulation in tumour tissue (Figure 1). ALA induced
higher porphyrin levels than any of its esters (P50.001).
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
1.6
1.4
1.2
0.4
0.2
0.0
P
o
r
p
h
y
r
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
µ
g
 
g
–
1
)
0                   5                  10                 15                 20                 25
Time (h)
ALA
Ethyl
Propyl
Butyl
Pentyl
Hexyl
Cyclohexyl
Benzyl
Figure 1 Porphyrin concentration in s.c. CaNT tumours following i.v. ad-
ministration of 0.12 mmol kg
71 ALA or its esteriﬁed derivatives. Data are
means+s.e. (n=4).
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ALA resulted in a dose-dependent reduction in the concentration
of porphyrins accumulating in the tumour (Table 1).
In normal murine tissues, the ability of i.v. ALA and its esters
(0.12 mmol kg
71) to induce porphyrin accumulation was tissue-
dependent (Figure 2). In skeletal muscle, porphyrin levels were
generally low, although benzyl-ALA was most effective. In skin
and liver, ALA generated the highest porphyrin levels, whereas in
the ileum, ALA, butyl-ALA and benzyl-ALA were similarly effective.
In the kidney, benzyl-ALA and ALA generated similar porphyrin
levels (0.124P40.05). As in the tumour, propyl-ALA failed to
induce porphyrin accumulation in any of the normal tissues exam-
ined.
Topical application of 20% ALA cream induced porphyrin accu-
mulation in the CaNT tumour, peaking 4 h after administration
(Figure 3). In contrast, 0.02–20% hexyl-ALA induced little or no
porphyrin accumulation in tumour tissue.
ALA and ALA-ester-induced generation of porphyrins in
cultured cells
All ALA-esters induced intracellular accumulation of porphyrins in
tumour cell clones (Figure 4a,b). When esters were administered at
their optimum concentrations, the resulting porphyrin levels were
similar to or above that induced by the optimum concentration
of ALA. When pentyl-, hexyl- and benzyl-ALA were administered
above concentrations of 6 mM,1m M and 10 mM respectively, cells
became rounded and detached from the substratum. This was not
seen for any other ALA-esters at the concentrations investigated.
HPLC analysis of porphyrins induced by ALA and ALA-
esters
Following i.v. administration of ALA at 0.12 mmol kg
71, PpIX
accounted for an average of 88% of the porphyrins in tumour
tissue, 98% in skin, 97% in skeletal muscle, 80% in liver, 87% in
ileum, and 89% in kidney. Following in vivo administration of
ALA-esters at 0.12 mmol kg
71, PpIX accounted for 83–100% of
the porphyrins generated by murine ileum depending on the ester
applied. When ALA or ALA-esters were used at their optimum
concentrations in vitro, PpIX accounted for 94–100% of porphyr-
ins generated.
Esterase activity in murine tissues and cultured cells
Non-speciﬁc esterase activity varied between the different tissues
examined (Table 2). In most cases, tissues with greater esterase
activity accumulated a higher concentration of porphyrin following
i.v. ester administration.
The mean esterase activity in cultured CaNT cells was 3.0+0.02
arbitary units/mg protein/s. In addition, serum-free DMEM
exposed to cells for 3 h exhibited a mean esterase activity of
946+7.7 a.u./ml/s (value corrected for background activity in the
medium of 59+16 a.u./ml/s). DISCUSSION
I.v. administration of ALA caused the accumulation of porphyrins in
CaNT tumour growing s.c. and in a variety of normal murine tissues
(Figures 1 and 2). Similarly, topical application of ALA to the skin
induced porphyrin accumulation in underlying tumour (Figure 3).
These results are in agreement with those of similar previous studies
(Cairnduff et al, 1995; de Bruijn et al, 1999). In all cases, the predo-
minant porphyrin species formed was protoporphyrin-IX.
In contrast, i.v. or topical administration of a range of ALA-
esters had relatively little or no effect on the porphyrin concentra-
tion in the s.c. CaNT tumour. However, when given i.v., all the
ALA-esters examined, with the exception of propyl-ALA, were able
to induce porphyrin accumulation in a variety of normal tissues
(Figure 2). This suggests that at least some murine tissues have
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Table 1 Porphyrin concentration in s.c. CaNT tumour tissue 1 h after i.v.
administration of ALA, hexyl- or benzyl-ALA. n=3 in all cases.
Mean porphyrin concentration+s.e. (mgg
71)
Drug dose
(mmol kg
71) ALA Hexyl Benzyl
0.0012 – 0.06+0.003 0.06+0.011
0.006 – 0.07+0.009 0.10+0.006
0.012 – 0.11+0.013 0.05+0.003
0.06 0.39+0.036 0.21+0.024 0.09+0.008
0.12 1.54+0.12 0.33+0.047 0.55+0.012
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Figure 2 Porphyrin concentration in selected normal mouse tissues 1h
after i.v. administration of 0.12 mmol kg
71 ALA or its esteriﬁed derivatives.
Data are means+s.e. (n=4).
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Figure 3 Porphyrin concentration in s.c. CaNT tumours following topical
application of emollient cream containing ALA (20% w/w) or hexyl-ALA
(0.02–20% w/w). Data are means+s.e. (n=4).
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and that the results obtained in tumour tissue are not a reﬂection
of murine metabolism per se.
Previous work in vitro has suggested that a number of ALA-
esters, including hexyl-ALA, are most effective when used at much
lower doses than ALA (Kloek et al, 1998; Lange et al, 1999; Uehlin-
ger et al, 2000). Here, we found that reducing the dose of i.v.
hexyl- or benzyl-ALA resulted in a dose-dependent reduction in
tumour porphyrin levels to that of untreated controls. Reducing
the dose of topical hexyl-ALA had no consistent effect on the very
low levels of porphyrins observed in tumours up to 6 h after appli-
cation. These ﬁndings strongly suggest that the relative inability of
ALA-esters to induce porphyrin accumulation in tumour tissue
compared to ALA was not the result of the esters being applied
at inappropriately high concentrations.
In contrast to the results with CaNT tumours, all ALA-esters
examined were able to induce similar or greater porphyrin concen-
trations than ALA in CaNT cells growing in vitro (Figure 4a,b). The
optimum concentration of each ALA-ester was related to the length
of the ester-linked chain, with longer-chain compounds inducing
maximum porphyrin levels at lower concentrations than the short-
er-chain derivatives. These ﬁndings are in broad agreement with
previous observations (Gaullier et al, 1997; Kloek et al, 1998;
Uehlinger et al, 2000).
It is not clear why the ability of ALA-esters to induce porphyrin
accumulation differed between CaNT cells in culture and those
growing as tumours in vivo. The observation that some non-fatty
normal murine tissues were able to utilise at least some of the
ALA-esters, including those with the longest carbon chains,
suggests reduced bioavailability via sequestration into lipid-rich
tissues is unlikely to explain the lack of effect in tumour tissue.
An alternative explanation is that introducing the tumour cells
to tissue culture modiﬁed their metabolism such that ALA-esters
could be more readily utilised. Up-regulation of intracellular
non-speciﬁc esterase activity could, for example, facilitate ester
hydrolysis and hence utilisation in porphyrin biosynthesis. With
the exception of liver, there was a tendency for tissues with higher
esterase activity to accumulate higher porphyrin concentrations
following i.v. ALA-ester administration (Table 2). Although ester-
ase activity in the cultured CaNT cells was relatively low, such
cells released esterase activity into the surrounding medium. It is
possible that pre-processing of ALA-esters whilst still in the
extra-cellular milieu could have made ALA available to the cells
in vitro in a way that may not have been available in vivo. Uptake
of ALA-ester destined for intra-cellular cleavage at the same time as
ALA derived from extra-cellular cleavage, may have resulted in
greater ALA availability for porphyrin biosynthesis than could have
been achieved by ALA-ester uptake alone. There is some evidence
that ALA and at least some ALA-esters are taken into cells via
different routes (Rud et al, 2000; Gederaas et al, 2001).
Clinical and animal studies do not yet provide a consistent
answer with regard to the efﬁcacy of ALA-esters (Peng et al,
1996; Lange et al, 1999; Fritsch et al, 1998; van den Akker et al,
2000). Here, we have found that several esters are less effective than
ALA at inducing porphyrin accumulation in a s.c. mouse tumour.
It is possible that the ability of ALA-esters to induce PpIX accumu-
lation may be dependent on factors such as tumour type, metabolic
status, or location, as well as on the actual ester applied. This may
have signiﬁcant implications for the clinical usefulness of this
group of compounds. Whether the level of esterase activity present
in the CaNT tumour is representative of that in other tumours,
and whether other tumours would display the same differential
response to ALA-esters applied in vitro and in vivo, remains to
be determined however.
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Figure 4 Porphyrin concentration in cultured CaNT cells after 3 h incu-
bation in serum-free medium containing ALA or (A) elthyl-, propyl- or bu-
tyl-ester (B) pentyl-, hexyl-, cyclohexyl- or benzyl-ester. Data are
means+s.e. (n=8).
Table 2 Porphyrin concentration in mouse tissues 1 h after i.v. administration of ALA or its esteriﬁed derivatives (0.12 mmol kg
71). n=4 in all cases.
Mean porphyrin concentration+s.e. (mgg
71)
Mean esterase
activity+s.e.
Tissue (a.u. mg
71 protein s
71) ALA Ethyl Propyl Butyl Pentyl Hexyl Cyclohexyl Benzyl
Ileum 692+3.82 2.11+0.49 0.70+0.20 0.04+0.1 1.92+0.61 0.51+0.11 1.44+0.37 0.94+0.22 2.19+0.48
Liver 332+1.18 4.96+0.34 0.55+0.08 70.04+0.03 0.21+0.09 0.13+0.02 0.25+0.05 0.13+0.01 0.14+0.20
Kidney 74+0.45 1.33+0.05 0.87+0.17 0.05+0.07 0.61+0.19 0.46+0.05 0.97+0.12 0.56+0.10 1.65+0.17
Skin 52+0.25 0.87+0.03 0.20+0.03 0.05+0.02 0.20+0.02 0.13+0.002 0.15+0.01 0.08+0.03 0.52+0.01
Tumour 11+0.07 1.41+0.12 0.10+0.02 0.002+0.03 0.09+0.02 0.09+0.01 0.20+0.05 0.02+0.01 0.41+0.01
Muscle 0.6+0.04 0.05+0.01 0.05+0.01 0.03+0.004 0.08+0.02 0.07+0.02 70.03+0.01 0.03+0.01 0.18+0.01
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least as effective as ALA at inducing protoporphyrin IX accumula-
tion in murine mammary carcinoma cells in vitro, but that the
same compounds are either ineffective, or much less effective than
ALA when administered in vivo. The greater complexity of the in
vivo environment and/or culture-induced changes in cell properties
may have been responsible for these differences. Such factors can
limit the ability of in vitro test systems to predict drug effectiveness
in vivo.
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